Promising Preclinical Results Position Ketamir-2 as a Potential Breakthrough Therapy That Surpasses Current Treatments, With Results to Be Presented at…
ST. LOUIS, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. a clinical-stage biotech company focused on the discovery and development…
New Data Confirms DIFS Improves Cognitive Function and Restores Brain Activity in Alzheimer's Patients HOUSTON, TX, Oct. 28, 2024 (GLOBE…
Strategic partnership explores therapeutic effect of Lisata’s novel cyclic peptide product candidate, certepetide, in combination with bevacizumabBASKING RIDGE, N.J., Oct.…
InStatin to secure exclusive worldwide licensing agreement of InVixa's inhaled statin solution to prevent and treat acute lung diseaseToronto, Ontario--(Newsfile…
KING OF PRUSSIA, Pa., Oct. 28, 2024 /PRNewswire/ -- RBQM innovator CluePoints has today announced that Richard Young has been…
INDIANAPOLIS, IN / ACCESSWIRE / October 28, 2024 / 3Aware, a pioneer in real-world evidence (RWE) solutions for the medical…
STOCKHOLM, SE / ACCESSWIRE / October 28, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical…
The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after…
New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate…